Longitudinal Improvements in Clinical and Functional Outcomes Following Initiation of Elexacaftor/tezacaftor/ivacaftor in Patients with Cystic Fibrosis

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Apr 29

PMID 38681615

Authors

Kadambari Vijaykumar

Hui Min Leung

Amilcar Barrios

Justin Wade

Heather Y Hathorne

David P Nichols

Guillermo J Tearney

Steven M Rowe

George M Solomon

Affiliations

Soon will be listed here.

Abstract

Background: Use of elexacaftor/tezacaftor/ivacaftor (ETI) for treatment of cystic fibrosis (CF) has resulted in unprecedented clinical improvements necessitating development of outcome measures for monitoring disease course. Intranasal micro-optical coherence tomography (μOCT) has previously helped detect and characterize mucociliary abnormalities in patients with CF. This study was done to determine if μOCT can define the effects of ETI on nasal mucociliary clearance and monitor changes conferred to understand mechanistic effects of CFTR modulators beyond CFTR activation.

Methods: 26 subjects, with at least 1 F508del mutation were recruited and followed at baseline (visit 1), +1 month (visit 2) and +6 months (visit 4) following initiation of ETI therapy. Clinical outcomes were computed at visits 1, 2 and 4. Intranasal μOCT imaging and functional metrics analysis including mucociliary transport rate (MCT) estimation were done at visits 1 and 2.

Results: Percent predicted forced expiratory volume in 1 s (ppFEV) showed a significant increase of +10.9 % at visit 2, which sustained at visit 4 (+10.6 %). Sweat chloride levels significantly decreased by -36.6 mmol/L and -41.3 mmol/L at visits 2 and 4, respectively. μOCT analysis revealed significant improvement in MCT rate (2.8 ± 1.5, visit 1 vs 4.0 ± 1.5 mm/min, visit 2; P = 0.048).

Conclusions: Treatment with ETI resulted in significant and sustained clinical improvements over 6 months. Functional improvements in MCT rate were evident within a month after initiation of ETI therapy indicating that μOCT imaging is sensitive to the treatment effect of HEMT and suggests improved mucociliary transport as a probable mechanism of action underlying the clinical benefits.

References

Donaldson S, Laube B, Mogayzel P, Corcoran T, Pilewski J, Ceppe A . Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study. J Cyst Fibros. 2021; 21(1):143-145. PMC: 8630086. DOI: 10.1016/j.jcf.2021.05.004. View

Birket S, Davis J, Fernandez C, Tuggle K, Oden A, Chu K . Development of an airway mucus defect in the cystic fibrosis rat. JCI Insight. 2018; 3(1). PMC: 5821204. DOI: 10.1172/jci.insight.97199. View

Graeber S, Vitzthum C, Pallenberg S, Naehrlich L, Stahl M, Rohrbach A . Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two Alleles. Am J Respir Crit Care Med. 2021; 205(5):540-549. DOI: 10.1164/rccm.202110-2249OC. View

Bell S, Mall M, Gutierrez H, Macek M, Madge S, Davies J . The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2019; 8(1):65-124. PMC: 8862661. DOI: 10.1016/S2213-2600(19)30337-6. View

Nichols D, Donaldson S, Frederick C, Freedman S, Gelfond D, Hoffman L . PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros. 2021; 20(2):205-212. PMC: 8686210. DOI: 10.1016/j.jcf.2021.02.003. View

Keiser N, Birket S, Evans I, Tyler S, Crooke A, Sun X . Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs. Am J Respir Cell Mol Biol. 2014; 52(6):683-94. PMC: 4491130. DOI: 10.1165/rcmb.2014-0250OC. View

Britto C, Ratjen F, Clancy J . Emerging Approaches to Monitor and Modify Care in the Era of Cystic Fibrosis Transmembrane Conductance Regulators. Clin Chest Med. 2022; 43(4):631-646. DOI: 10.1016/j.ccm.2022.06.006. View

Leung H, Birket S, Hyun C, Ford T, Cui D, Solomon G . Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies. Sci Transl Med. 2019; 11(504). PMC: 6886258. DOI: 10.1126/scitranslmed.aav3505. View

Nichols D, Paynter A, Heltshe S, Donaldson S, Frederick C, Freedman S . Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2021; 205(5):529-539. PMC: 8906485. DOI: 10.1164/rccm.202108-1986OC. View

10.

Hoegger M, Fischer A, McMenimen J, Ostedgaard L, Tucker A, Awadalla M . Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science. 2014; 345(6198):818-22. PMC: 4346163. DOI: 10.1126/science.1255825. View

11.

Markovetz M, Garbarine I, Morrison C, Kissner W, Seim I, Gregory Forest M . Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis. J Cyst Fibros. 2022; 21(6):959-966. DOI: 10.1016/j.jcf.2022.04.008. View

12.

Batson B, Zorn B, Radicioni G, Livengood S, Kumagai T, Dang H . Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence. Am J Respir Cell Mol Biol. 2022; 67(2):253-265. PMC: 9348562. DOI: 10.1165/rcmb.2021-0359OC. View

13.

Regard L, Martin C, Burnet E, Da Silva J, Burgel P . CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. Cells. 2022; 11(11). PMC: 9179538. DOI: 10.3390/cells11111769. View

14.

Pearson K, Mayer-Hamblett N, Goss C, Retsch-Bogart G, Vandalfsen J, Burks P . The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network. J Cyst Fibros. 2020; 20(2):195-197. PMC: 7834129. DOI: 10.1016/j.jcf.2020.12.007. View

15.

LeGrys V, Yankaskas J, Quittell L, Marshall B, Mogayzel Jr P . Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr. 2007; 151(1):85-9. DOI: 10.1016/j.jpeds.2007.03.002. View

16.

Hisert K, Heltshe S, Pope C, Jorth P, Wu X, Edwards R . Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Am J Respir Crit Care Med. 2017; 195(12):1617-1628. PMC: 5476912. DOI: 10.1164/rccm.201609-1954OC. View

17.

Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019; 394(10212):1940-1948. PMC: 7571408. DOI: 10.1016/S0140-6736(19)32597-8. View

18.

Ma J, Tang C, Kang L, Voynow J, Rubin B . Cystic Fibrosis Sputum Rheology Correlates With Both Acute and Longitudinal Changes in Lung Function. Chest. 2018; 154(2):370-377. DOI: 10.1016/j.chest.2018.03.005. View

19.

Donaldson S, Laube B, Corcoran T, Bhambhvani P, Zeman K, Ceppe A . Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. JCI Insight. 2018; 3(24). PMC: 6338313. DOI: 10.1172/jci.insight.122695. View

20.

Nichols D, Morgan S, Skalland M, Vo A, Van Dalfsen J, Singh S . Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. J Clin Invest. 2023; 133(10). PMC: 10178839. DOI: 10.1172/JCI167957. View